Prognostic significance of splicing factor gene mutations in AML; therapy resistance in multiple myeloma; the effects of KIT ligand deletion on HSC homeostasis

This podcast explores the prognostic significance of splicing factor gene mutations in AML and therapy resistance in multiple myeloma. It discusses the impact of Venetoclax treatment on survival rates in AML patients. The importance of developing new prognostic models considering these factors is highlighted. The podcast also delves into subclonal evolution patterns and resistance mechanisms in multiple myeloma patients, emphasizing the significance of integrative multi-omics analysis. The use of a multi-omics approach to evaluate treatments and the limitations of this approach are discussed.